Filtered By:
Therapy: Hormonal Therapy

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 218 results found since Jan 2013.

Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis.
Conclusions: Low quality evidence suggests that sex steroid therapy may increase LDL-C and TG and decrease HDL-C levels in FTM, while oral estrogens may increase TGs in MTF. Data about patient important outcomes remain sparse. PMID: 28945852 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - September 13, 2017 Category: Endocrinology Authors: Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, Murad MH Tags: J Clin Endocrinol Metab Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review.
Abstract Recent reports estimate that 0.6% of adults in the United States, or approximately 1.4 million persons, identify as transgender. Despite gains in rights and media attention, the reality is that transgender persons experience health disparities, and a dearth of research and evidence-based guidelines remains regarding their specific health needs. The lack of research to characterize cardiovascular disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone therapy (CSHT) limits appropriate primary and specialty care. As with hormone therapy in cisgender persons (that is, those ...
Source: Annals of Internal Medicine - July 25, 2017 Category: Internal Medicine Authors: Streed CG, Harfouch O, Marvel F, Blumenthal RS, Martin SS, Mukherjee M Tags: Ann Intern Med Source Type: research

Risk of Stroke With Various Types of Menopausal Hormone Therapies Brief Report
Conclusions—In a national setting, we found an increased risk of stroke, based on ischemic stroke, with oral hormone therapies that was comparable to findings from randomized studies. We found no risk of stroke with transdermal application and a reduced risk with vaginal estrogen.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Ellen Lokkegaard, Lars Hougaard Nielsen, Niels Keiding Tags: Epidemiology, Risk Factors, Women, Cerebrovascular Disease/Stroke Brief Reports Source Type: research

Does coffee make you live longer?
Conclusion This study, conducted on a large number of people across Europe, was backed up by similar findings in the US. It appears to show some association between people who drink higher amounts of coffee and a reduced risk of death. But the "potentially beneficial clinical implications" need to be considered carefully for a number of reasons: Although the analyses were adjusted for some confounding variables, there may be a number of other factors that differ between the groups that account for the differences in death, such as socioeconomic status, family history, other medical conditions, and use of medic...
Source: NHS News Feed - July 12, 2017 Category: Consumer Health News Tags: Food/diet Source Type: news

The 2017 hormone therapy position statement of The North American Menopause Society
Abstract: The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and a...
Source: Menopause - June 27, 2017 Category: OBGYN Tags: Position Statement Source Type: research

Luteolin: How To Reduce Breast Cancer Risk
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes n...
Source: Al Sears, MD Natural Remedies - June 23, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Women losing out over hormone therapy fears, some experts say
The risk of heart attack, stroke or breast cancer due to hormone replacement therapy has been overstated, and that has scared away some women who could benefit from it, the Society of Obstetricians and Gynaecologists of Canada said at its annual conference in Ottawa this week.
Source: CBC | Health - June 23, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Custom-compounded bioidentical hormone therapy: why so popular despite potential harm? The case against routine use.
Abstract Wide rejection of conventional hormone therapy (HT) after the initial publication of the Women's Health Initiative (WHI) led to unjustified use of custom-compounded bioidentical hormones. In the USA, it became an unregulated drug manufacturer industry in disguise, without proper control and making false claims and misleading advertisements. Manufacturing quality is not ensured. Unspecific harm from compounding has occurred on a large scale, such as deaths from infected products and end-stage renal failure plus carcinoma due to confusion between different Chinese herbs. Oral estrogens increase venous throm...
Source: Climacteric - May 18, 2017 Category: Geriatrics Authors: L'Hermite M Tags: Climacteric Source Type: research

Abstract 226: Strokes Worse in Women at 24 hours but Severity Reduced in Younger Women With Hormone Therapy Session Title: Poster Session II
Conclusion: Women in this study had more severe 24 hour AIS outcomes than men but this improved with HRT use in women younger than 80 years. This cannot be fully explained by age differences as there could be other underlying factors. Improving 24 hour NIHSS may correctly predict later outcomes following AIS. Further study of HRT use in AIS outcomes is justified.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Brown, A., Onteddu, S., Joiner, R., Benton, T., Culp, W., Lowery, C. Tags: Session Title: Poster Session II Source Type: research

Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study
Conclusions: Our results do not provide strong evidence for a protective association between postmenopausal HT use and AD or dementia, although we observed a reduced AD risk among those with long-term self-reported HT use.
Source: Neurology - March 12, 2017 Category: Neurology Authors: Imtiaz, B., Tuppurainen, M., Rikkonen, T., Kivipelto, M., Soininen, H., Kröger, H., Tolppanen, A.-M. Tags: Alzheimer's disease, Cohort studies ARTICLE Source Type: research

Study: Hormone replacement therapy may help improve women's heart health, overall survival
(Cedars-Sinai Medical Center) Hormone replacement therapy has long been controversial as studies have associated it with health benefits and risks. While some studies suggest that it lowers the risk of osteoporosis and improves some aspects of heart health, others link it to higher risk of cancer and stroke. Now, a new imaging study suggests that women using hormone replacement therapy to relieve menopause symptoms face a lower risk of death and show lower levels of atherosclerosis compared to women who do not use hormone therapy.
Source: EurekAlert! - Cancer - March 8, 2017 Category: Cancer & Oncology Source Type: news

SIRT1-dependent AMPK pathway in the protection of estrogen against ischemic brain injury.
CONCLUSION: Our data support that estrogen protects against ischemic stroke through preventing neuron death via the SIRT1-dependent AMPK pathway. PMID: 28256111 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - March 1, 2017 Category: Neuroscience Authors: Guo JM, Shu H, Wang L, Xu JJ, Niu XC, Zhang L Tags: CNS Neurosci Ther Source Type: research

Anti-M üllerian Hormone Trajectories Are Associated With Cardiovascular Disease in Women: Results From the Doetinchem Cohort Study.
CONCLUSIONS: These results indicate that AMH trajectories in women are independently associated with CVD risk. Therefore, we postulate that the decline of circulating AMH levels may be part of the pathophysiology of the increased cardiovascular risk of earlier menopause. Confirmation of this association and elucidation of its underlying mechanisms are needed to place these results in a clinical perspective. PMID: 28153992 [PubMed - in process]
Source: Circulation - February 6, 2017 Category: Cardiology Authors: de Kat AC, Verschuren WM, Eijkemans MJ, Broekmans FJ, van der Schouw YT Tags: Circulation Source Type: research

The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Authors: Parish SJ, Gillespie JA Abstract This review describes the evolving role of oral hormone therapy (HT) for treating menopausal symptoms and preventing osteoporosis, focusing on conjugated estrogens/bazedoxifene (CE/BZA). Estrogens alleviate hot flushes and prevent bone loss associated with menopause. In nonhysterectomized women, a progestin should be added to estrogens to reduce the risk of endometrial cancer. Use of HT declined since the Women's Health Initiative (WHI) studies showed that HT does not prevent coronary heart disease (CHD) and that conjugated estrogens/medroxyprogesterone acetate increased th...
Source: Postgraduate Medicine - February 1, 2017 Category: Internal Medicine Tags: Postgrad Med Source Type: research